Synonyms- |
Introduction- |
Target |
Mechanism α3β4 receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism α3β4 receptor modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Mechanism Nicotinic acetylcholine receptor alpha4/beta2/alpha5 antagonists [+1] |
Active Org. Atacama Therapeutics, Inc.Startup |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Start Date31 May 2021 |
Sponsor / Collaborator |
Start Date14 Apr 2020 |
Sponsor / Collaborator |
Start Date31 Jan 2020 |
Sponsor / Collaborator Atacama Therapeutics, Inc.Startup |